Sanofi

Pursue Progress. Discover Extraordinary.

Science has been our calling from the beginning. Sanofi’s heritage of turning the impossible into the possible stretches back to the 19th century — a rich history of healthcare innovation built by diverse companies united by one shared purpose. More than 150 years later, that spirit lives in everything we do and every person we serve — from the patients who take our medicines, to the healthcare professionals who trust us, to the 83,000+ employees and communities around the world who make it all possible. And today, we’re writing the next chapter of that legacy.

We are an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth.

Better is out there. Better medications, better outcomes, better science. And it all starts with people like you — from different backgrounds, in different locations, doing different roles — united by a single mission: we chase the miracles of science to improve people’s lives.

Take the most important step in your career and help us change the lives of patients, families, and communities for the better.

Explore Open Roles →

  • Featured Employer
What could we achieve together? Sign up today and discover our latest opportunities as soon as they’re available.
Reinvention is in our DNA. It’s what drove our evolution from a small French enterprise to one of the world’s leading biopharma companies — present in 70+ countries and growing. Whether it’s harnessing AI to shorten drug-discovery timelines, pioneering transformative treatments, or building trust in healthcare systems worldwide, you could be helping our teams make life better for patients, partners, and communities.

This is where you grow your career. We open the door for you to explore new roles, take on stretch assignments, and connect with people driven by a shared purpose. Our culture of high performance and belonging is grounded in four core values:: Aim Higher, Act for Patients, Be Bold, and Lead Together.

At Sanofi, we believe every person can lead from where they are. You’ll learn to grow your skills and evolve as a leader through our Leadership Frame. Connect with mentors via our Career Hub, and explore new possibilities through “gigs”, where you’ll work on short-term projects to try something new on another team. You’ll do it all with our full support, increasing your exposure to business leaders, and expanding your network across the industry.
All Well, together. We support healthy bodies, healthy minds, healthy financials, and a healthy working culture for all Sanofians. Our dedication to improving people’s lives starts at home, with the health and wellbeing of our employees and their families.
We want you to share your voice and challenge us, even when it might feel uncomfortable. We’ll help turn your ideas into action, based on tangible measures. Because it’s action, not intent, that makes change sustainable and gives us our Diversity Edge.

We’re the first in pharma to have a Diversity, Equity and Inclusion (DE&I) Board with external members. And every member of our Executive Committee is represented either on the DE&I board or as a sponsor of a global Employee Resource Group (ERG). Diversity is our strength. Boldly, proudly and unapologetically. We’re All In on DE&I. Come and be part of it.
What is the Sanofi Feeling?

You are unique. How you feel on any given day is unique. Who you are with, and the environment you’re in, has the power to shape and enhance how you feel. At Sanofi, it’s not just about the chair you sit in. We’ve blended art with science and looked at every detail to match your uniqueness.

We’re transforming healthcare and improving lives through our work, our people, and our stories. You’ll get a glimpse of what life here is like, you’ll hear inspiring stories and you’ll dive into the projects that reveal the miracles of science. Let’s live extraordinarily.
AWARDS
  • Sanofi Human Rights Campaign award.png
  • Sanofi award_usa-2.png
  • Sanofi award_usa-3.png
  • 2023 Best Places to Work
  • 2022 Best Places to Work
NEWS
For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.
The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, follows the pharma’s potential $1.4 billion COVID vaccine licensing deal with Novavax last year, plus a number of other big-ticket commitments outside of the vaccine space.
Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be three times larger than what AbbVie’s blockbuster Humira ever achieved.
Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move forward with another protein degrader from the biotech, designed to target immune-mediated diseases.
The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.
Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal. Across biopharma, companies are sometimes willing to put it all on the line for the right buyout. Novartis’ recent acquisition of Regulus for $800 million upfront provides a case study.
HHS Secretary Robert F. Kennedy Jr. made waves this week, firing the remaining members of the CDC’s Advisory Committee on Immunization Practices; Metsera’s amylin drug produced weight loss of 8.4% at 36 days; and FDA leaders gathered last week to discuss the future of cell and gene therapy, a sector that has been in turmoil since the ousting of CBER Chief Peter Marks.
Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow through with M&A after earning a right of first negotiation. Sanofi, on the other hand, almost always does, as it did with Vigil recently.
Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler presentations and more severe and prolonged lesions compared to patients with lighter skin.
JOBS
IN THE PRESS